Theraclone Sciences has completed the dosing of the first patient in a randomised, double-blind, dose-escalation Phase I trial to investigate TCN-032 as a treatment for influenza A virus.

The trial is supported in part by Theraclone’s multi-year R&D agreement with Zenyaku Kogyo to identify conserved, essential antibody targets and develop candidates for the treatment of pandemic and severe seasonal influenza.

TCN-032 was discovered using Theraclone’s I-STAR platform.

The Phase I study will enrol up to 40 healthy adult volunteers to assess the safety profile of a single intravenous administration of TCN-032 compared to placebo.

The study will also provide pharmacokinetic and immunogenicity data.

Study results are expected in the first half of 2012 and are required for commencement of proof-of-concept clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.